Compounds having the following structure (IB') and pharmaceutically acceptable salts thereof are provided. Pharmaceutical compositions comprising the compounds, and methods for use of the compounds for treating diseases associated with overexpression of a cyclin-dependent kinase (CDK) are also provided.